Bertagnolli, Goldberg, Gunn, Brundage, and Theiler receive awards at Alliance fall meeting

To keep the early clinical trial enterprise in the U.S., HHS pledges to simplify regulatory requirements

HHS earlier this week rolled out a cluster of initiatives related to simplifying clinical trials, presenting these measures as a government-wide effort to maintain America’s leadership in early-stage drug development.

OMB draft rule politicizing research should be rescinded, House Dems urge in a letter to Bhattacharya

Democratic leaders of the House Committee on Energy and Commerce are urging NIH Director Jay Bhattacharya to voice objections to a proposed rule from the Office of Management and Budget that would give the administration unprecendented political control over government-funded science.

Dana-Farber names its under-construction freestanding hospital: the Lavine Bekenstein Cancer Hospital

Dana-Farber Cancer Institute announced the name of its 300-bed, freestanding cancer hospital, which is now under construction and will span 450,000 square feet across 10 inpatient floors: the Lavine Bekenstein Cancer Hospital. The building is expected to open in 2031.

June 26, 2026

Vol.52 No.25

Clinical Roundup

Sigvotatug vedotin misses OS primary endpoint vs. docetaxel in phase III trial in previously treated metastatic non-squamous NSCLC

Sigvotatug vedotin, an integrin beta-6 directed antibody-drug conjugate, did not show a statistically significant improvement in the primary endpoint of overall survival, compared to docetaxel, according to the results of the phase III SigVie-002 study (previously known as Be6A Lung-01).

June 26, 2026

Vol.52 No.25

Clinical Trials & Tribulations

What NHS-Galleri taught us—and what it didn’t

On May 30, GRAIL reported the full results of the NHS-Galleri trial in an oral presentation at the ASCO Annual Meeting.

June 18, 2026

Vol.52 No.24

By Scott D. Ramsey and Ruth Etzioni

Clinical Trials & Tribulations

The NHS-Galleri trial has and will continue to provide critical insights to refine future MCED studies

The NHS-Galleri trial presented at ASCO was the largest, prospective, randomized trial of a multicancer early detection test (MCED) to date. The study enrolled approximately 143,000 asymptomatic adults (ages 50-77) and was the first of its kind to assess clinical utility of an MCED test for cancer screening.

June 18, 2026

Vol.52 No.24

By Bryan Bassig, Catherine R. Marinac, David M. Routman, Elizabeth K. O'Donnell, Jennifer Keating Litton, Karthik V. Giridhar, Kennedy Ng Yao Yi, Kurt Giles, Nima Nabavizadeh, Ora K. Gordon, Rebecca Kaltman and Shawn Kothari

Bertagnolli, Goldberg, Gunn, Brundage, and Theiler receive awards at Alliance fall meeting

YOU MAY BE INTERESTED IN

To keep the early clinical trial enterprise in the U.S., HHS pledges to simplify regulatory requirements

OMB draft rule politicizing research should be rescinded, House Dems urge in a letter to Bhattacharya

Dana-Farber names its under-construction freestanding hospital: the Lavine Bekenstein Cancer Hospital

Sigvotatug vedotin misses OS primary endpoint vs. docetaxel in phase III trial in previously treated metastatic non-squamous NSCLC

What NHS-Galleri taught us—and what it didn’t

The NHS-Galleri trial has and will continue to provide critical insights to refine future MCED studies

Renew today!

Subscriber content

Never miss an issue!

Login